Loading…
OKYO Pharma Ltd
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -32.7% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Year-end price | $1.38 | $2.07 | $1.15 | $1.77 | |
| P/B | — | 5.9x | — | — | — |
| EPS | -$0.24 | -$0.12 | -$0.57 | -$0.61 | |
| ROE | — | -72.55% | — | — | — |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| GUTSFractyl Health Inc | $0.55 | — | — | — | — | $88.03M |
| HYPRHyperfine, Inc. | $0.83 | — | 2.4x | — | -96.97% | $88.36M |
| ATRAAtara Biotherapeutics, Inc. | $8.81 | — | — | — | — | $88.43M |
| ECORelectroCore, Inc. | $9.63 |
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Company description provided by Yahoo Finance.
| — |
| — |
| — |
| — |
| $86.78M |
| INCRIntercure Ltd. | $5.78 | — | 0.8x | — | -9.27% | $86.72M |
| RLYBRallybio Corp | $16.86 | 2.1x | 0.9x | — | 64.86% | $89.57M |